Philippe GENNE

About Philippe GENNE

Philippe Genne is a leading French life sciences executive, widely recognized for combining scientific depth, entrepreneurial drive, and long-term value creation in precision oncology. He holds a PhD in Pharmacology from the University of Dijon, completed in 1992, and earned his HDR in 1994. He began his career at Debiopharm, where he led a clinical development program focused on a multidrug resistance inhibitor derived from his doctoral research. From 1992 to 1998, he oversaw preclinical development and Phase I and Phase II clinical studies in collaboration with Inserm. That early experience gave him a rare operational understanding of the entire translational chain, from discovery to clinical proof of concept. In 1995, he founded Oncodesign Biotechnology in Dijon. That company became the foundation of a long entrepreneurial journey centered on oncology drug discovery and the development of integrated pharmacology capabilities. Under his leadership, Oncodesign evolved into a listed company on Euronext Growth and built a strong position in translational research and drug discovery services. He later led a major strategic restructuring that split the group into two independent businesses, Oncodesign Services and Oncodesign Precision Medicine, while also overseeing the sale of Oncodesign Services to specialist investors and the listing of Oncodesign Precision Medicine in 2022. Today, Philippe Genne serves as Chief Executive Officer and Chairman of Oncodesign Precision Medicine. In this role, he is responsible for strategic direction, scientific prioritization, external partnerships, and the company’s broader mission in precision medicine and oncology. He is known for his ability to align science, strategy, and capital allocation in a sector where execution discipline is critical. Beyond his corporate responsibilities, he has also played an active role in the French life sciences ecosystem, including co-founding the AFSSI in 2012 and holding leadership responsibilities within Medicen. His career reflects a consistent commitment to innovation, industrialization of research, and the creation of specialized platforms able to address unmet medical needs.